Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
CT-388 is an orally or injectably administered dual GLP-1R and GIPR agonist that is in the early stages of development
By modulating dopamine levels, these medications could potentially impact the reinforcing effects of addictive behaviors
It also stabilizes blood sugar, which normalizes insulin levels, helping to burn fat. Prescriptions will be supported by the comprehensive features of Noom Med, including asynchronous telehealth, access to care coordinators, Noom Weight, premium 1:1 coaching, and medication fulfillment through Nooms partner pharmacies, all enhanced by Nooms Medication Companion with Muscle Defense TM
The treatment, an investigational once-weekly triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously, met its primary endpoints in both trials, delivering substantial weight loss across high-risk populations including adults with type 2 diabetes and those with severe obesity and established cardiovascular disease
Unlike existing approved therapies, it simultaneously targets GLP-1, GIP, and glucagon receptors, a mechanism that early clinical data suggest may produce substantial metabolic effects
US$ 28.83
US$ 21.55
US$ 20.34
US$ 21.97
